|
gptkbp:instanceOf
|
gptkb:monoclonal_antibody
antineoplastic agent
|
|
gptkbp:administeredBy
|
gptkb:pertuzumab
gptkb:carboplatin
intravenous infusion
docetaxel
paclitaxel
|
|
gptkbp:approvalYear
|
1998
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
L01XC03
|
|
gptkbp:biosimilar
|
yes
|
|
gptkbp:biosimilarNames
|
gptkb:Ogivri
gptkb:Herzuma
gptkb:Kanjinti
gptkb:Ontruzant
gptkb:Trazimera
|
|
gptkbp:brand
|
gptkb:Herceptin
|
|
gptkbp:CASNumber
|
180288-69-1
|
|
gptkbp:clinicalTrialPhase
|
Phase III
|
|
gptkbp:contraindication
|
pregnancy
hypersensitivity to trastuzumab
|
|
gptkbp:cost
|
high
|
|
gptkbp:developedBy
|
gptkb:Genentech
|
|
gptkbp:discoveredBy
|
gptkb:UCLA_researchers
|
|
gptkbp:firstApprovedIndication
|
metastatic breast cancer
|
|
gptkbp:form
|
solution for infusion
|
|
gptkbp:halfLife
|
5-12 days
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
trastuzumab
|
|
gptkbp:immunoglobulinType
|
gptkb:IgG1
|
|
gptkbp:KEGGID
|
D08141
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:marketedAs
|
gptkb:Roche
|
|
gptkbp:mechanismOfAction
|
induces antibody-dependent cellular cytotoxicity
inhibits HER2-mediated signaling
|
|
gptkbp:molecularWeight
|
148,000 Da
|
|
gptkbp:origin
|
humanized monoclonal antibody
|
|
gptkbp:patentExpired
|
yes
|
|
gptkbp:pregnancyCategory
|
D (US)
|
|
gptkbp:PubChem_CID
|
123631
DB00072
CHEMBL1201587
|
|
gptkbp:routeOfAdministration
|
intravenous
|
|
gptkbp:sideEffect
|
pulmonary toxicity
cardiotoxicity
infusion reactions
|
|
gptkbp:storage
|
2-8°C
|
|
gptkbp:target
|
gptkb:HER2/neu_receptor
|
|
gptkbp:UNII
|
P188ANX8CK
|
|
gptkbp:usedFor
|
gptkb:HER2-positive_breast_cancer
HER2-positive gastric cancer
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
yes
|
|
gptkbp:bfsParent
|
gptkb:L01EM01
gptkb:Tukysa
gptkb:Herceptin
gptkb:Kadcyla
gptkb:Perjeta
gptkb:ALTTO_trial
gptkb:APHINITY_trial
|
|
gptkbp:bfsLayer
|
6
|